Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome.
暂无分享,去创建一个
[1] A. Manolis,et al. Sensitivity and specificity of programmed atrial stimulation for induction of supraventricular tachycardias , 1988, Clinical cardiology.
[2] N. Fineberg,et al. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. , 1986, The American journal of cardiology.
[3] E. Shinebourne,et al. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. , 1986, The American journal of cardiology.
[4] M. Shenasa,et al. Evaluation of flecainide acetate in rapid atrial fibrillation complicating wolff‐parkinson‐white syndrome , 1985, Clinical cardiology.
[5] K. Kuck,et al. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. , 1984, The American journal of cardiology.
[6] E. Prystowsky,et al. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. , 1984, Circulation.
[7] A. Camm,et al. Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. , 1983, The American journal of cardiology.
[8] W. Dassen,et al. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. , 1980, The American journal of cardiology.
[9] T. D. Sellers,et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. , 1979, The New England journal of medicine.